Trade Teva Pharma Ind Adr Rep 1 - TEVA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Teva Pharmaceutical Industries Ltd ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 10.17 |
Open* | 10.15 |
1-Year Change* | 32.51% |
Day's Range* | 9.83 - 10.15 |
52 wk Range | 7.09-11.45 |
Average Volume (10 days) | 6.04M |
Average Volume (3 months) | 207.39M |
Market Cap | 10.46B |
P/E Ratio | -100.00K |
Shares Outstanding | 1.12B |
Revenue | 15.02B |
EPS | -2.00 |
Dividend (Yield %) | N/A |
Beta | 1.18 |
Next Earnings Date | Nov 1, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 26, 2023 | 10.17 | 0.00 | 0.00% | 10.17 | 10.37 | 10.16 |
Sep 25, 2023 | 10.23 | -0.05 | -0.49% | 10.28 | 10.28 | 10.01 |
Sep 22, 2023 | 10.33 | 0.03 | 0.29% | 10.30 | 10.51 | 10.14 |
Sep 21, 2023 | 10.31 | -0.27 | -2.55% | 10.58 | 10.60 | 10.30 |
Sep 20, 2023 | 10.68 | 0.33 | 3.19% | 10.35 | 10.69 | 10.35 |
Sep 19, 2023 | 10.27 | -0.26 | -2.47% | 10.53 | 10.54 | 10.24 |
Sep 18, 2023 | 10.53 | 0.04 | 0.38% | 10.49 | 10.63 | 10.49 |
Sep 15, 2023 | 10.55 | 0.04 | 0.38% | 10.51 | 10.63 | 10.51 |
Sep 14, 2023 | 10.54 | 0.22 | 2.13% | 10.32 | 10.56 | 10.28 |
Sep 13, 2023 | 10.32 | 0.31 | 3.10% | 10.01 | 10.33 | 10.00 |
Sep 12, 2023 | 10.02 | 0.00 | 0.00% | 10.02 | 10.11 | 9.96 |
Sep 11, 2023 | 10.02 | 0.31 | 3.19% | 9.71 | 10.02 | 9.71 |
Sep 8, 2023 | 9.60 | 0.25 | 2.67% | 9.35 | 9.63 | 9.35 |
Sep 7, 2023 | 9.32 | -0.02 | -0.21% | 9.34 | 9.36 | 9.24 |
Sep 6, 2023 | 9.46 | -0.04 | -0.42% | 9.50 | 9.51 | 9.37 |
Sep 5, 2023 | 9.53 | -0.22 | -2.26% | 9.75 | 9.76 | 9.52 |
Sep 1, 2023 | 9.81 | 0.00 | 0.00% | 9.81 | 9.90 | 9.77 |
Aug 31, 2023 | 9.74 | 0.15 | 1.56% | 9.59 | 9.83 | 9.58 |
Aug 30, 2023 | 9.66 | -0.04 | -0.41% | 9.70 | 9.76 | 9.66 |
Aug 29, 2023 | 9.72 | 0.12 | 1.25% | 9.60 | 9.78 | 9.59 |
Teva Pharma Ind Adr Rep 1 Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 14925 | 15878 | 16659 | 16887 | 18854 |
Revenue | 14925 | 15878 | 16659 | 16887 | 18854 |
Cost of Revenue, Total | 7487 | 8014 | 8870 | 9351 | 10558 |
Gross Profit | 7438 | 7864 | 7789 | 7536 | 8296 |
Total Operating Expense | 17024 | 14162 | 20231 | 17330 | 20537 |
Selling/General/Admin. Expenses, Total | 3445 | 3402 | 3519 | 3667 | 4052 |
Research & Development | 838 | 967 | 997 | 1010 | 1213 |
Unusual Expense (Income) | 5239 | 1721 | 6739 | 3191 | 4838 |
Other Operating Expenses, Total | 15 | -41 | -20 | -28 | -286 |
Operating Income | -2099 | 1716 | -3572 | -443 | -1683 |
Interest Income (Expense), Net Non-Operating | -904 | -988 | -833 | -825 | -894 |
Other, Net | -62 | -70 | -1 | 3 | -19 |
Net Income Before Taxes | -3065 | 658 | -4406 | -1265 | -2596 |
Net Income After Taxes | -2427 | 447 | -4238 | -987 | -2304 |
Minority Interest | 53 | -39 | 109 | 2 | 322 |
Equity In Affiliates | 21 | 9 | 138 | -13 | -71 |
Net Income Before Extra. Items | -2353 | 417 | -3991 | -998 | -2053 |
Total Extraordinary Items | 0 | 0 | -97 | ||
Net Income | -2353 | 417 | -3991 | -998 | -2150 |
Total Adjustments to Net Income | 1 | -1 | -249 | ||
Income Available to Common Excl. Extra. Items | -2353 | 417 | -3990 | -999 | -2302 |
Income Available to Common Incl. Extra. Items | -2353 | 417 | -3990 | -999 | -2399 |
Dilution Adjustment | |||||
Diluted Net Income | -2353 | 417 | -3990 | -999 | -2399 |
Diluted Weighted Average Shares | 1110 | 1107 | 1095 | 1091 | 1021 |
Diluted EPS Excluding Extraordinary Items | -2.11982 | 0.37669 | -3.64384 | -0.91567 | -2.25465 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Diluted Normalized EPS | 0.94806 | 1.43282 | 0.35648 | 0.98547 | 0.82537 |
Depreciation / Amortization | 99 | 126 | 139 | 162 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 3878 | 3661 | 3884 | 3595 | 3786 |
Revenue | 3878 | 3661 | 3884 | 3595 | 3786 |
Cost of Revenue, Total | 1959 | 2015 | 1784 | 1885 | 1958 |
Gross Profit | 1919 | 1646 | 2100 | 1710 | 1828 |
Total Operating Expense | 4524 | 3659 | 4739 | 3176 | 4735 |
Selling/General/Admin. Expenses, Total | 910 | 842 | 837 | 777 | 849 |
Research & Development | 240 | 234 | 210 | 175 | 228 |
Depreciation / Amortization | 20 | 21 | |||
Unusual Expense (Income) | 1448 | 571 | 1854 | 321 | 1683 |
Other Operating Expenses, Total | -33 | -3 | 54 | -2 | -4 |
Operating Income | -646 | 2 | -855 | 419 | -949 |
Interest Income (Expense), Net Non-Operating | -216 | -260 | -237 | -230 | -225 |
Other, Net | -52 | -9 | -23 | 14 | |
Net Income Before Taxes | -914 | -258 | -1101 | 166 | -1160 |
Net Income After Taxes | -898 | -239 | -1255 | 59 | -260 |
Minority Interest | 35 | 33 | 32 | -3 | 27 |
Equity In Affiliates | 1 | 1 | -1 | 0 | |
Net Income Before Extra. Items | -862 | -206 | -1222 | 55 | -233 |
Net Income | -862 | -206 | -1222 | 55 | -233 |
Total Adjustments to Net Income | -1 | 1 | 1 | 1 | 1 |
Income Available to Common Excl. Extra. Items | -863 | -205 | -1221 | 56 | -232 |
Income Available to Common Incl. Extra. Items | -863 | -205 | -1221 | 56 | -232 |
Diluted Net Income | -863 | -205 | -1221 | 56 | -232 |
Diluted Weighted Average Shares | 1120 | 1115 | 1113 | 1119 | 1110 |
Diluted EPS Excluding Extraordinary Items | -0.77054 | -0.18386 | -1.09704 | 0.05004 | -0.20901 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.08375 | 0.16359 | -0.01429 | 0.23651 | 0.77653 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 12051 | 12573 | 13005 | 13464 | 13794 |
Cash and Short Term Investments | 2801 | 2165 | 2177 | 1975 | 1784 |
Cash & Equivalents | 2801 | 2165 | 2177 | 1975 | 1782 |
Short Term Investments | 2 | ||||
Total Receivables, Net | 3696 | 4529 | 4581 | 5676 | 5822 |
Accounts Receivable - Trade, Net | 3696 | 4529 | 4581 | 5676 | 5822 |
Total Inventory | 3833 | 3818 | 4403 | 4422 | 4731 |
Prepaid Expenses | 1162 | 1075 | 945 | 870 | 899 |
Other Current Assets, Total | 559 | 986 | 899 | 521 | 558 |
Total Assets | 44006 | 47666 | 50640 | 57470 | 60683 |
Property/Plant/Equipment, Total - Net | 6158 | 6477 | 6855 | 6950 | 6868 |
Property/Plant/Equipment, Total - Gross | 11676 | 11718 | 11947 | 11864 | 11796 |
Accumulated Depreciation, Total | -5518 | -5241 | -5092 | -4914 | -4928 |
Goodwill, Net | 17633 | 20040 | 20624 | 24846 | 24917 |
Intangibles, Net | 6270 | 7466 | 8923 | 11232 | 14005 |
Other Long Term Assets, Total | 1894 | 1110 | 1233 | 978 | 1038 |
Total Current Liabilities | 11469 | 11027 | 13164 | 13674 | 14322 |
Accounts Payable | 1887 | 1686 | 1756 | 1718 | 1853 |
Accrued Expenses | 2810 | 2880 | 2581 | 2680 | 2738 |
Notes Payable/Short Term Debt | 23 | 23 | 514 | 514 | 516 |
Current Port. of LT Debt/Capital Leases | 2086 | 1403 | 2674 | 1831 | 1700 |
Other Current Liabilities, Total | 4663 | 5035 | 5639 | 6931 | 7515 |
Total Liabilities | 36109 | 37388 | 40614 | 43498 | 45976 |
Total Long Term Debt | 19103 | 21617 | 22731 | 24562 | 26691 |
Long Term Debt | 19103 | 21617 | 22731 | 24562 | 26691 |
Deferred Income Tax | 548 | 784 | 964 | 1096 | 2140 |
Minority Interest | 794 | 966 | 1035 | 1091 | 1087 |
Other Liabilities, Total | 4195 | 2994 | 2720 | 3075 | 1736 |
Total Equity | 7897 | 10278 | 10026 | 13972 | 14707 |
Redeemable Preferred Stock | 0 | ||||
Common Stock | 57 | 57 | 57 | 56 | 56 |
Additional Paid-In Capital | 27688 | 27561 | 27443 | 27312 | 27210 |
Retained Earnings (Accumulated Deficit) | -12882 | -10529 | -10946 | -6956 | -5958 |
Treasury Stock - Common | -4128 | -4128 | -4128 | -4128 | -4142 |
Unrealized Gain (Loss) | 0 | 0 | 0 | 1 | |
Other Equity, Total | -2838 | -2683 | -2400 | -2312 | -2460 |
Total Liabilities & Shareholders’ Equity | 44006 | 47666 | 50640 | 57470 | 60683 |
Total Common Shares Outstanding | 1110.9 | 1103.33 | 1096.51 | 1092.19 | 1089.39 |
Total Preferred Shares Outstanding | 0 | 0 | 0 | ||
Long Term Investments | 61 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 11501 | 12051 | 11453 | 12164 | 12451 |
Cash and Short Term Investments | 2143 | 2801 | 2225 | 2058 | 2175 |
Cash & Equivalents | 2143 | 2801 | 2225 | 2058 | 2175 |
Total Receivables, Net | 3435 | 3696 | 3730 | 4471 | 4253 |
Accounts Receivable - Trade, Net | 3435 | 3696 | 3730 | 4471 | 4253 |
Total Inventory | 4118 | 3833 | 3859 | 4049 | 4012 |
Prepaid Expenses | 1253 | 1162 | 1045 | 1052 | 1064 |
Other Current Assets, Total | 552 | 559 | 594 | 534 | 947 |
Total Assets | 43456 | 44006 | 44252 | 45932 | 47059 |
Property/Plant/Equipment, Total - Net | 6171 | 6158 | 5990 | 6181 | 6396 |
Goodwill, Net | 17799 | 17633 | 18433 | 18837 | 19986 |
Intangibles, Net | 5964 | 6270 | 6393 | 6700 | 7116 |
Other Long Term Assets, Total | 2021 | 1894 | 1983 | 2050 | 1110 |
Total Current Liabilities | 10411 | 11469 | 11534 | 10996 | 11613 |
Accounts Payable | 2381 | 1887 | 1635 | 1901 | 1750 |
Accrued Expenses | 2699 | 2717 | 2537 | 2579 | 3078 |
Notes Payable/Short Term Debt | 23 | 23 | 23 | 23 | 23 |
Current Port. of LT Debt/Capital Leases | 1000 | 2086 | 2746 | 1696 | 2054 |
Other Current Liabilities, Total | 4308 | 4756 | 4593 | 4797 | 4708 |
Total Liabilities | 35595 | 36109 | 35484 | 36895 | 37715 |
Total Long Term Debt | 19668 | 19103 | 18497 | 20363 | 20840 |
Long Term Debt | 19668 | 19103 | 18497 | 20363 | 20840 |
Deferred Income Tax | 550 | 548 | 503 | 532 | 666 |
Minority Interest | 751 | 794 | 751 | 791 | 916 |
Other Liabilities, Total | 4215 | 4195 | 4199 | 4213 | 3680 |
Total Equity | 7861 | 7897 | 8768 | 9037 | 9344 |
Common Stock | 57 | 57 | 57 | 57 | 57 |
Additional Paid-In Capital | 27719 | 27688 | 27652 | 27625 | 27587 |
Retained Earnings (Accumulated Deficit) | -13086 | -12882 | -11660 | -11716 | -11484 |
Treasury Stock - Common | -4128 | -4128 | -4128 | -4128 | -4128 |
Other Equity, Total | -2701 | -2838 | -3153 | -2801 | -2688 |
Total Liabilities & Shareholders’ Equity | 43456 | 44006 | 44252 | 45932 | 47059 |
Total Common Shares Outstanding | 1120.41 | 1110.9 | 1110.64 | 1110.56 | 1110.35 |
Total Preferred Shares Outstanding | |||||
Unrealized Gain (Loss) |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -2406 | 456 | -4099 | -1000 | -2472 |
Cash From Operating Activities | 1590 | 798 | 1216 | 748 | 2446 |
Cash From Operating Activities | 1308 | 1330 | 1557 | 1722 | 1842 |
Deferred Taxes | -1059 | -120 | -696 | -985 | -837 |
Non-Cash Items | 2490 | 833 | 6642 | 1907 | 5736 |
Cash Taxes Paid | 543 | 495 | 709 | 552 | 420 |
Cash Interest Paid | 948 | 913 | 846 | 840 | 815 |
Changes in Working Capital | 1257 | -1701 | -2188 | -896 | -1823 |
Cash From Investing Activities | 656 | 1523 | 863 | 1355 | 1866 |
Capital Expenditures | -548 | -562 | -578 | -525 | -651 |
Other Investing Cash Flow Items, Total | 1204 | 2085 | 1441 | 1880 | 2517 |
Cash From Financing Activities | -1487 | -2172 | -1885 | -1926 | -3351 |
Financing Cash Flow Items | -118 | -6 | -5 | -11 | -57 |
Total Cash Dividends Paid | 0 | 0 | -52 | -22 | |
Issuance (Retirement) of Stock, Net | 0 | ||||
Issuance (Retirement) of Debt, Net | -1369 | -2166 | -1880 | -1863 | -3272 |
Foreign Exchange Effects | -123 | -128 | 8 | 16 | -142 |
Net Change in Cash | 636 | 21 | 202 | 193 | 819 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -238 | -2406 | -1152 | -1211 | -952 |
Cash From Operating Activities | -145 | 1590 | 617 | 73 | -49 |
Cash From Operating Activities | 304 | 1308 | 1002 | 681 | 323 |
Deferred Taxes | -106 | -1059 | -1214 | -1258 | -175 |
Non-Cash Items | 259 | 2490 | 974 | 949 | 196 |
Changes in Working Capital | -364 | 1257 | 1007 | 912 | 559 |
Cash From Investing Activities | 181 | 656 | 488 | 341 | 161 |
Capital Expenditures | -139 | -548 | -406 | -284 | -157 |
Other Investing Cash Flow Items, Total | 320 | 1204 | 894 | 625 | 318 |
Cash From Financing Activities | -706 | -1487 | -776 | -336 | 2 |
Financing Cash Flow Items | -5 | -118 | -115 | -40 | 2 |
Issuance (Retirement) of Debt, Net | -701 | -1369 | -661 | -296 | 0 |
Foreign Exchange Effects | 12 | -123 | -269 | -185 | -62 |
Net Change in Cash | -658 | 636 | 60 | -107 | 52 |
Total Cash Dividends Paid |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Phoenix Investment and Finances Ltd | Investment Advisor | 3.0069 | 33703410 | 11569608 | 2023-06-30 | MED |
Ion Asset Management Israel Ltd | Hedge Fund | 2.9498 | 33063004 | 4872280 | 2023-06-30 | MED |
Clal Insurance Enterprises Holdings Ltd. | Investment Advisor | 2.8205 | 31614669 | 12779003 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.7298 | 30597449 | 14795 | 2023-06-30 | LOW |
Menora Mivtachim Insurance Ltd. | Insurance Company | 2.3712 | 26578560 | -62658 | 2023-06-30 | LOW |
Lingotto Investment Management LLP | Investment Advisor/Hedge Fund | 2.1602 | 24213261 | 7121351 | 2023-06-30 | MED |
Migdal Insurance and Financial Holdings Ltd | Insurance Company | 2.1096 | 23646440 | 299880 | 2023-06-30 | |
Rubric Capital Management LP | Hedge Fund | 1.67 | 18718362 | 14218556 | 2023-06-30 | MED |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.3894 | 15573344 | -3991484 | 2023-06-30 | LOW |
Millennium Management LLC | Hedge Fund | 1.2517 | 14030069 | 7835223 | 2023-06-30 | HIGH |
Slate Path Capital LP | Investment Advisor | 1.1096 | 12437000 | 12437000 | 2023-06-30 | MED |
Capital International Investors | Investment Advisor | 0.8906 | 9982828 | 0 | 2023-06-30 | LOW |
Camber Capital Management LP | Hedge Fund | 0.7583 | 8500000 | 5500000 | 2023-06-30 | MED |
Abrams Capital, L.L.C. | Hedge Fund | 0.7107 | 7966433 | 0 | 2023-06-30 | LOW |
Eversept Partners, LP | Hedge Fund | 0.6841 | 7668044 | 1473472 | 2023-06-30 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.6376 | 7146599 | 394037 | 2023-06-30 | LOW |
AustralianSuper | Pension Fund | 0.6195 | 6943247 | 4523700 | 2023-06-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.5835 | 6540060 | 5400 | 2023-06-30 | HIGH |
Jane Street Capital, L.L.C. | Research Firm | 0.5538 | 6206988 | 3138239 | 2023-06-30 | HIGH |
BSN Capital Partners Ltd | Investment Advisor | 0.5353 | 6000000 | 6000000 | 2022-12-31 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Teva Company profile
Teva Pharmaceutical (TEVA) is a multinational pharmaceutical company set up in Jerusalem in 1901. The business’s primary focus is generic drugs. Teva is a world leader in specialty medicines. Teva production facilities are based in Israel, North America, South America and Europe. Their generic drugs portfolio includes over 1,000 products that represent therapeutic versions of innovative drugs. Their specialty medicines portfolio features a wide scope of treatments of the CNS disorders. The company’s shares are traded on the New York Stock Exchange (NYSE) and on the Tel Aviv Stock Exchange (TASE). To stay informed on the latest Teva Pharma share price, follow Capital.com.Industry: | Pharmaceuticals (NEC) |
5 Bazel St
P O B 3190
PETAH TIKVA
49131
IL
Income Statement
- Annual
- Quarterly
News

How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com